Anupam Rasayan India Ltd (ANURAS) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Anupam Rasayan reported consolidated operating revenue of INR 390 crores in Q3 FY25, a 32% YoY increase compared to Q3 FY24 and a 33% QoQ increase compared to Q2 FY25. This growth was driven by the Pharma and Polymer segments and a robust performance by Tanfac.
- The Pharma segment contributed 23% of sales, and the Polymer segment contributed 10% of sales in the nine months of FY25. Both segments are expected to contribute meaningfully to the overall revenue for the full year FY25 and continue this growth trend into FY26.
- The Agrochemical segment faced weak demand, particularly from Europe, but improvement is expected in the coming quarters.
- Consolidated EBITDA margin for Q3 FY25 was 31% due to a favorable product mix and strong margins from Tanfac.
- The company anticipates resuming its growth trajectory in FY26, targeting a 30% to 35% revenue increase.
- A 9.2-megawatt hybrid power plant was commissioned in October 2024, representing a INR 59 crore investment. This plant is expected to generate annual energy cost savings of approximately INR 15 crores.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.